The Latest Cardiac and Vascular News
LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 /PRNewswire/ — The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary…
MIAMI LAKES, Fla.–(BUSINESS WIRE)– #Cordis–Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at
TOKYO–(BUSINESS WIRE)– #Cordis–Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function. The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 9
SELUTION DeNovo Trial – the largest randomized Drug Eluting Balloon trial – demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug Eluting Stent treatment strategy in de novo lesions. SELUTION4ISR, a randomized controlled trial, proves SELUTION SLR™ DEB is an alternative to…
12-month data from pivotal randomized studies underscore Cordis’ commitment to shaping the future of cardiovascular care. MIAMI LAKES, Fla., Oct. 21, 2025 /PRNewswire/ — Cordis, a global leader in interventional cardiovascular technologies, will share late-breaking 12-month results from…
